Esomeprazole
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Esomeprazole: From Acid-Related Disorders to Duodenogastric Reflux
One-Sentence Summary
Esomeprazole (Nexium) is the S-isomer of omeprazole — a proton pump inhibitor (PPI) with established efficacy in gastro-oesophageal reflux disease (GERD), reflux esophagitis, and Helicobacter pylori eradication. The TxGNN model predicts it may be effective for Duodenogastric Reflux with a score of 99.53%, currently supported by 0 clinical trials and 1 narrative review specifically for this indication. Notably, the closely related indication of duodenal ulcer (TxGNN rank 3) carries robust L1 evidence from multiple completed Phase 3 RCTs, reflecting the drug’s well-established acid-suppression pharmacology across the gastroduodenal spectrum.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | GERD, reflux esophagitis, H. pylori eradication, NSAID-associated ulcer prevention (no registered product found in India market) |
| Predicted New Indication | Duodenogastric Reflux |
| TxGNN Prediction Score | 99.53% |
| Evidence Level | L4 |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this evidence pack. Based on published literature, Esomeprazole is a proton pump inhibitor (PPI) that irreversibly blocks the H⁺/K⁺-ATPase enzyme on gastric parietal cells, dramatically reducing acid secretion and prolonging intragastric pH above 4. As the S-isomer of omeprazole, it achieves more consistent pharmacokinetic exposure than its racemate, which translates to superior acid control in head-to-head trials.
The mechanistic connection to duodenogastric reflux is indirect and only partially plausible. Duodenogastric reflux is characterised by the retrograde movement of bile and duodenal contents into the stomach — the primary pathological agent here is bile, not acid. PPI therapy has no direct pharmacological mechanism to block bile reflux. However, in mixed-reflux scenarios where acid and bile act synergistically to damage the gastric mucosa, reducing acid may attenuate the co-injury effect, providing some clinical benefit.
The TxGNN model’s very high prediction score (99.53%) most likely reflects the dense knowledge-graph connections between esomeprazole and the broader family of acid-related gastroduodenal diseases — including GERD, peptic ulcer, and reflux esophagitis — rather than a validated mechanistic pathway specific to duodenogastric reflux. This prediction should therefore be interpreted with caution and treated as a hypothesis-generating signal.
Clinical Trial Evidence
Currently no related clinical trials registered for Esomeprazole in duodenogastric reflux.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 18679668 | 2008 | Narrative Review | European Journal of Clinical Pharmacology | Comprehensive PPI update confirming esomeprazole as first-line for peptic ulcer, H. pylori infection, GERD, NSAID-induced GI lesions, and Zollinger-Ellison syndrome; duodenogastric reflux is not addressed as a distinct indication |
India Market Information
No registered products found. Esomeprazole holds no approved licenses on record in the India market within this dataset.
Safety Considerations
Drug Interactions (168 total identified; key interactions listed below):
| Interacting Drug | Severity |
|---|---|
| Acalabrutinib | Major |
| Atazanavir | Major |
| Abametapir (topical) | Moderate |
| Apalutamide | Moderate |
| Armodafinil | Moderate |
| Bosutinib | Moderate |
| Atorvastatin | Moderate |
| Amphotericin B | Moderate |
| Hydrochlorothiazide | Moderate |
| Acetylsalicylic acid | Minor |
Key warnings and contraindications data are not available in this evidence pack. Please refer to the package insert for complete safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Although Esomeprazole’s TxGNN prediction score for duodenogastric reflux is extremely high (99.53%), the mechanistic link is indirect (acid suppression does not directly address bile reflux), there are no dedicated clinical trials for this indication, and the sole supporting publication is a general PPI narrative review with no specific duodenogastric reflux data. The evidence is insufficient to advance beyond hypothesis generation at this stage.
To proceed, the following is needed:
- Dedicated prospective clinical studies or RCTs evaluating esomeprazole specifically in duodenogastric (bile) reflux populations
- Mechanistic studies clarifying whether acid suppression meaningfully modifies outcomes in isolated versus mixed (acid + bile) reflux
- Complete MOA data from DrugBank (DG002 remediation) to support or challenge the mechanistic rationale
- TFDA/CDSCO package insert review to fill the warning and contraindication data gap (DG001 remediation)
- Consider whether the L1-evidence duodenal ulcer indication (TxGNN rank 3) represents a higher-priority repurposing opportunity that warrants a separate regulatory evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.